2. Metabolic Enzyme/Protease
  3. MMP
  4. Saikosaponin C

Saikosaponin C is an orally active MMP-2 inducer. Saikosaponin C induces the survival, growth, migration and capillary tube formation of endothelial cells. Saikosaponin C inhibits the early stage of hepatitis C virus infection. Saikosaponin C can be used in research related to ischemic tissue diseases, chronic kidney diseases and hepatitis C virus infection.

For research use only. We do not sell to patients.

Saikosaponin C

Saikosaponin C Chemical Structure

CAS No. : 20736-08-7

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
20 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Saikosaponin C:

Saikosaponin C Related Antibodies

Top Publications Citing Use of Products

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Saikosaponin C is an orally active MMP-2 inducer. Saikosaponin C induces the survival, growth, migration and capillary tube formation of endothelial cells. Saikosaponin C inhibits the early stage of hepatitis C virus infection. Saikosaponin C can be used in research related to ischemic tissue diseases, chronic kidney diseases and hepatitis C virus infection[1][2][3].

Cellular Effect
Cell Line Type Value Description References
A549 IC50
> 50 μM
Compound: 15
Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay
[PMID: 26259802]
Bcap37 IC50
> 50 μM
Compound: 15
Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay
[PMID: 26259802]
Hep 3B2 IC50
> 50 μM
Compound: 15
Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay
[PMID: 26259802]
HepG2 IC50
> 50 μM
Compound: 15
Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay
[PMID: 26259802]
MCF7 IC50
> 50 μM
Compound: 15
Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay
[PMID: 26259802]
In Vitro

Saikosaponin C (100 μM; 72 h) increases primary human umbilical vein endothelial cell viability, with a 1.75-fold increase relative to untreated cells[1].
Saikosaponin C (100 μM; 72 h) promotes primary human umbilical vein endothelial cell growth, resulting in a cell count of 12.9× 105 per plate[1].
Saikosaponin C (100 μM; 4, 8, 24 h) enhances primary human umbilical vein endothelial cell migration, significantly narrowing scratch wound gaps at 4, 8, and 24 h post-treatment[1].
Saikosaponin C (100 μM; 8, 24 h) promotes primary human umbilical vein endothelial cell invasion through matrigel, increasing invaded cell counts at 8 and 24 h post-seeding[1].
Saikosaponin C (10-100 μM; 8 h) induces primary human umbilical vein endothelial cell capillary tube formation, with 10 μM treatment increasing total capillary length to 2.68-fold relative to untreated cells[1].
Saikosaponin C (100 μM; 4, 8 h) increases matrix metalloproteinase-2 activity and matrix metalloproteinase-2 mRNA expression in primary human umbilical vein endothelial cells, with 1.8-fold higher mRNA expression at 4 h and 1.5-fold higher mRNA expression at 8 h relative to untreated cells[1].
Saikosaponin C (100 μM; 4, 8, 24 h) increases vascular endothelial growth factor protein expression and activates p42/p44 mitogen-activated protein kinase in primary human umbilical vein endothelial cells, with 2.6-fold higher VEGF protein at 8 h and 3.2-fold higher phosphorylated ERK at 4 h relative to untreated cells[1].
Saikosaponin C exhibits stable binding affinity with HK2 protein, with a binding energy of -9.528 kcal/mol[2].
Saikosaponin C (2-16 μg/mL; 24 h) is non-toxic to TCMK1 renal tubular epithelial cells at concentrations of 2, 4, and 8 μg/mL after 24 h of incubation, while 12 and 16 μg/mL reduce cell viability[2].
Saikosaponin C (2-8 μg/mL; 24 h post-TGF-β stimulation) inhibits TGF-β-induced fibrosis in TCMK1 renal tubular epithelial cells, with 4 and 8 μg/mL concentrations significantly suppressing fibronectin and α-SMA expression after 24 h of treatment[2].
Saikosaponin C (4-8 μg/mL; 24 h post-TGF-β stimulation) exerts anti-inflammatory and anti-apoptotic effects in TGF-β-stimulated TCMK1 renal tubular epithelial cells, with 4 and 8 μg/mL concentrations reducing inflammatory cytokine expression and late apoptotic cell proportions after 24 h of treatment[2].
Saikosaponin C (4-8 μg/mL; 24 h post-TGF-β stimulation) suppresses HK2/PKM2/LDHA-mediated glycolysis in TGF-β-stimulated TCMK1 renal tubular epithelial cells, with 4 and 8 μg/mL concentrations reducing HK2 expression, PKM2 and LDHA phosphorylation, and lactate production after 24 h of treatment[2].
Saikosaponin C (0-1000 μM) inhibits Jc1-GLuc HCV infection of Huh-7.5 cells with an EC50 of 86.12 μM[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Saikosaponin C Related Antibodies

Cell Viability Assay[2]

Cell Line: Mouse renal tubular epithelial TCMK1 cells
Concentration: 2-16 μg/mL
Incubation Time: 24 h
Result: Exhibited no adverse effect on TCMK1 cell viability at 2, 4, and 8 μg/mL; significantly reduced cell viability at 12 and 16 μg/mL.
In Vivo

Saikosaponin C (50-100 mg/kg/day; p.o.; daily; 7 days) ameliorates unilateral ureteral obstruction-induced chronic kidney disease renal injury and fibrosis via dose-dependent suppression of renal inflammation, fibrotic marker expression, and the HK2/PKM2/LDHA glycolytic axis, with 50 mg/kg/day showing superior renal protection efficacy[2].
Saikosaponin C (50 mg/kg/day; p.o.; daily) ameliorates adenine-induced chronic kidney disease renal injury and fibrosis by improving renal function, reducing fibrotic marker expression, and lowering serum lactate levels[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (male, 8 weeks old, 22-25 g, unilateral ureteral obstruction-induced)[2]
Dosage: 50 mg/kg/day; 100 mg/kg/day
Administration: p.o.; daily; 7 days
Result: Reduced renal tubular injury percentages, with the 50 mg/kg/day group showing superior renal protection compared to the 100 mg/kg/day group.
Substantially downregulated renal mRNA expression of inflammatory markers TNF-α, IL-1β, and IL-6.
Reduced renal protein expression of fibrotic markers fibronectin (Fn) and α-smooth muscle actin (α-SMA) as measured by immunohistochemistry and Western blot.
Molecular Weight

927.12

Formula

C48H78O17
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O[C@H]([C@@H](O)[C@]([H])(O[C@@H]1C(C)(C)[C@@](CC[C@]2(C)[C@]3([H])C=C[C@@]45[C@@]2(C)C[C@H](O)[C@]6(CO5)[C@@]4([H])CC(C)(C)CC6)([H])[C@]3(C)CC1)O[C@@H]7CO[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H]7O[C@]9([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (107.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.0786 mL 5.3930 mL 10.7861 mL
5 mM 0.2157 mL 1.0786 mL 2.1572 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.70 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.70 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.0786 mL 5.3930 mL 10.7861 mL 26.9652 mL
5 mM 0.2157 mL 1.0786 mL 2.1572 mL 5.3930 mL
10 mM 0.1079 mL 0.5393 mL 1.0786 mL 2.6965 mL
15 mM 0.0719 mL 0.3595 mL 0.7191 mL 1.7977 mL
20 mM 0.0539 mL 0.2697 mL 0.5393 mL 1.3483 mL
25 mM 0.0431 mL 0.2157 mL 0.4314 mL 1.0786 mL
30 mM 0.0360 mL 0.1798 mL 0.3595 mL 0.8988 mL
40 mM 0.0270 mL 0.1348 mL 0.2697 mL 0.6741 mL
50 mM 0.0216 mL 0.1079 mL 0.2157 mL 0.5393 mL
60 mM 0.0180 mL 0.0899 mL 0.1798 mL 0.4494 mL
80 mM 0.0135 mL 0.0674 mL 0.1348 mL 0.3371 mL
100 mM 0.0108 mL 0.0539 mL 0.1079 mL 0.2697 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Saikosaponin C Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Saikosaponin C20736-08-7MMPMatrix metalloproteinasesHuh-7.5 cellsendothelial cellsrenal fibrosis markersinflammatory cytokinesp42/p44 mitogen-activated protein kinasematrix metalloproteinase-2HK2/PKM2/LDHA signaling axishepatitis C virusvascular endothelial growth factorTCMK1 renal tubular epithelial cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Saikosaponin C
Cat. No.:
HY-N0249
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.